Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Abivax
- 04 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.
- 04 Oct 2017 Planned primary completion date changed from 31 Jan 2018 to 30 Jun 2018.
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.